The FDA on May 29, 2020 approved TECENTRIQ® in combination with AVASTIN® for patients with unresectable or metastatic Hepatocellular Carcinoma (HCC) who have not received prior systemic therapy. TECENTRIQ® and AVASTIN® are products of Genentech Inc.
Bottom Ad
Advertisement
Subscribe
